Prof. H.P. Beerlage PhD

foto

Prof. PhD H.P. Beerlage

Position
Full Professor
Main activities
Research, Other
Specialisation
Urology
Focus of research

Prostate cancer is the most common malignancy in men and 2500 men die from prostate cancer every year in The Netherlands. In order to diagnose prostate cancer the PSA bloodtest is widely used but suffers from low sensitivity and specificity. This leads to unneccesary invasive testing (prostate biopsy) on the one hand with associated complications in many patients while in over 60% of cases no significant tumor is found on biopsies. On the other hand this test may be omitted unjustified in patients who have a significant malignancy. The key solution to this problem is better imaging. Prostate cancer is poorly visible on imaging although significant progress has been made in recent years using MR scanning. However MR is expensive and over 10% of prostate tumors will be missed. Ideally it would be possible to make a correct diagnosis with imaging only, selecting those who do need a biopsy, or even better being able to justly omit biopsy at all. Together with our collegues at the Technical University Eindhoven we investigate multiparametric ultrasound scanning in the diagnosis of prostate cancer. To date our research shows contrast enhanced ultasound scanning of the prostate is approaching the results of MR scanning. But the field of ultrasound scanning is evolving tremendously resulting in the development of many new parameters. These all have to be tested in clinical setting which we do in AmsterdamUMC and in our clinical partner hospital.

Key publications
  • Mannaerts Christophe K., Gayet Maudy, Verbeek Jan F. M., Engelbrecht Marc R. W., Savci Heijink Dilara D., Jager Gerrit J., Gielens M.P.M., van der Linden H., Beerlage Harrie P., de Reijke Theodorus M., Wijkstra Hessel, Roobol Monique J. Prostate cancer risk assessment in biopsy-naïve patients: The Rotterdam prostate cancer risk calculator in multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS biopsy European Urology Oncology 2018;1 (2):109-117 [PubMed]
  • van Sloun Ruud J. G., Wildeboer Rogier R., Mannaerts Christophe K., Postema Arnoud W., Gayet Maudy, Beerlage Harrie P., Salomon Georg, Wijkstra Hessel, Mischi Massimo Deep Learning for Real-time, Automatic, and Scanner-adapted Prostate (Zone) Segmentation of Transrectal Ultrasound, for Example, Magnetic Resonance Imaging–transrectal Ultrasound Fusion Prostate Biopsy European urology focus 2019 [PubMed]
  • Alberts Arnout R., Roobol Monique J., Verbeek Jan F. M., Schoots Ivo G., Chiu Peter K., Osses Daniël F., Tijsterman Jasper D., Beerlage Harrie P., Mannaerts Christophe K., Schimmöller Lars, Albers Peter, Arsov Christian Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators European urology 2019;75 (2):310-318 [PubMed]
  • Gayet Maudy, van der Aa Anouk, Schmitz Peter, Beerlage Harrie P., Schrier Bart Ph, Mulders Peter F. A., Mischi Massimo, Wijkstra Hessel 3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer detection World journal of urology 2016;34 (9):1255-1260 [PubMed]
  • Gayet Maudy, van der Aa Anouk, Beerlage Harrie P., Schrier Bart Ph, Mulders Peter F. A., Wijkstra Hessel The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review BJU international 2016;117 (3):392-400 [PubMed]
All Publications